BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
LEP
,
T cell receptor signaling pathway
,
Obesity
,
Lung
,
Alcohol
,
Valproic acid
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
stage N2
Summary
General Info
Curated Studies
Most Correlated Studies
Colorectal tumor expression profiles
The TOP trial of anthracycline monotherapy in ER- breast cancer patients
Tongue carcinomas with TNM staging and normal control comparisons
Clinical analysis of stage II-III breast cancer
Colorectal cancer liver metastases, primary tumors and prospective response to FOLFIRI chemotherapy
Explore Curated Studies Results
Literature
Most Relevant Literature
Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum.
Real-World Analysis of Survival and Treatment Efficacy in Stage IIIA-N2 Non-Small Cell Lung Cancer.
A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in …
Survival impact of unexpected N2 in stage IIIB/N2 non-small cell lung cancer patients.
Surgery is a promising strategy for improving overall survival for stage III-N2 non-small cell lung …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer
Cardiac Substructure Radiation Dose and Early Clinical Monitoring of Stage N2-3 Non-Small Cell Lung …
NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation
Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.
A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ